Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $330
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $310 to $330.
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $310 to $330.